Macrolide-Resistant Mycoplasma pneumoniae, United State
Emerging Infectious Diseases Aug 2015 V.21 N.8
Xiaotian ZhengComments to Author , Stella Lee, Rangaraj Selvarangan, Xuan Qin, Yi-Wei Tang, Jeffrey Stiles, Tao Hong, Kathleen Todd, Amy E. Ratliff, Donna M. Crabb, Li Xiao, T. Prescott Atkinson, and Ken B. Waites
Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA (X. Zheng, S. Lee, K. Todd); The Children’s Mercy Hospitals and Clinics, Kansas City, Missouri, USA (R. Selvarangan); Seattle Children’s Hospital, Seattle, Washington, USA (X. Qin); Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, New York, USA (Y.W. Tang, J. Stiles); Hackensack University Medical Center, Hackensack, New Jersey, USA (T. Hong); University of Alabama at Birmingham, Birmingham, Alabama, USA (A.E. Ratliff, D.M. Crabb, L. Xiao, T.P. Atkinson, K.B. Waites)
Macrolide-resistant Mycoplasma pneumoniae (MRMP) is highly prevalent in Asia and is now being reported from Europe.
Few data on MRMP are available in the United States.
Using genotypic and phenotypic methods, we detected high-level MRMP in 13.2% of 91 M. pneumoniae–positive specimens from 6 US locations.